Apotex and Intas expand biosimilars agreement
This article was originally published in Scrip
Executive Summary
Apotexand Intas Biopharmaceuticals of India have expanded their agreement to develop biosimilars to include peg-filgrastim for neutropenia. Intas already manufactures and markets Neupeg, a recombinant pegylated granulocyte colony stimulating factor (GCSF) in India.